NCT00836914View on ClinicalTrials.gov

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Allergic Rhinitis

Interventions

DRUG

CAL-101

CAL-101 100mg capsules administered orally twice a day (BID) for 7 days

DRUG

Placebo

Placebo capsules administered orally BID for 7 days

Trial Locations (1)

Unknown

Vienna Challenge Chamber, Vienna

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY